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Abstract
Purpose To assess current uterine ﬁbroid embolisation
(UFE) practice in European countries and determine the
clinical environment for UFE in different hospitals.
Material and Methods In May 2009, an invitation for an
online survey was sent by e-mail to all members of the
Cardiovascular and Interventional Radiologic Society of
Europe, representing a total number of 1,250 different
candidate European treatment centres. The survey covered
21 questions concerning local UFE practice.
Results A total of 282 respondents completed the ques-
tionnaire. Fifteen questionnaires were excluded because
they were doubles from centres that had already returned a
questionnaire. The response rate was 267 of 1,250 centres
(21.4%). Ninety-four respondents (33%) did not perform
UFE and were excluded, and six centres were excluded
because demographic data were missing. The remaining
167 respondents from different UFE centres were included
in the study. Twenty-six percent of the respondents were
from the United Kingdom (n = 43); 16% were from
Germany (n = 27); 11% were from France (n = 18); and
the remaining 47% (n = 79) were from other European
countries. Most centres (48%, n = 80) had 5 to 10 years
experience with UFE and performed 10 to 50 procedures
annually (53% [n = 88]) of respondents). Additional
demographic data, as well as speciﬁc data on referral of
patients, UFE techniques used, and periprocedural and
postprocedural, care will be provided.
Conclusion Although UFE as an alternative treatment for
hysterectomy or myomectomy is widespread in Europe, its
impact on the management of the patient with symptomatic
ﬁbroids seems, according to the overall numbers of UFE
procedures, somewhat disappointing. Multiple factors
might be responsible for this observation.
Keywords Uterine ﬁbroids  Uterine ﬁbroid
embolisation  Survey
Introduction
Uterine ﬁbroids are the most common benign tumours in
women of childbearing age. Symptomatic ﬁbroids can
cause a diversity of symptoms, which can be divided into
four categories: bleeding symptoms (irregular and/or heavy
menstrual bleeding), pain (in the pelvic region and the
back), bulk-related symptoms (pressure on bladder and
bowel as well as increase in abdominal circumference), and
subfertility [1]. These symptoms often lead to medical or
surgical treatments.
During the last two decades, minimally invasive thera-
peutic options for uterine ﬁbroids have increased consid-
erably. Uterine ﬁbroid embolisation (UFE) was introduced
in 1994 and is currently a well acknowledged and proven
alternative to surgical treatment [2, 3].
UFE is a percutaneous trancatheter embolisation
technique using embolisation material to occlude the
(end-)arteries supplying the ﬁbroid. Devascularisation
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which may result in effective alleviation of symptoms.
However, after the introduction of UFE as an alternative
to more invasive approaches, a real widespread break-
through, especially in general interventional radiology
(IR), did not occur.
Information on UFE still seems to be unavailable to a
large number of women in Europe, and many gynaecolo-
gists do not provide the option of UFE, or they inaccurately
inform patients, using misleading facts. Speciﬁc data on the
number of centres and interventionalists performing UFE
in Europe and the number of UFE procedures per centre do
not exist.
This publication reports the outcome of a survey among
European interventional radiologists concerning UFE
treatment. The purpose of this study was to determine
actual data on the current clinical practice of UFE in
European countries.
Materials and Methods
In May 2009, we designed a survey to assess current UFE
practice in European countries. All professionally active
European members of the Cardiovascular and Interven-
tional Radiologic Society of Europe (CIRSE) were invited
by e-mail to participate in this study. The total number of
different candidate treatment facilities in Europe was
1,250. The questionnaire consisted of 21 questions con-
cerning local clinical practice of UFE and related topics
(see Appendix for complete questionnaire). The online
button-driven questionnaire was designed for easy handling
with a simple set-up to be sure that as many interventional
radiologists as possible would participate in this study and
could be able to complete all ﬁelds.
The ﬁrst questions referred to demographic data con-
cerning the treatment facility in which respondents were
working. The next question was if UFE was performed by
the responding interventional radiologist. In case the answer
was ‘‘no,’’ the questionnaire was excluded from the data-
base. The remaining respondents were asked about
the interventional group in their facility (number of inter-
ventional radiologists and how many of them performed
UFE). Respondents had to indicate the time period when
their hospital staff started performing UFE as well as the
number of UFE procedures performed per year. Respon-
dents were asked to describe the referral pattern of patients
(self-referral, e.g., directly to IR, referral by gynaecologist,
or referral by general practitioner) categorized as percent-
ages adding up to 100%. The questionnaire also assessed
who was responsible for preprocedural and postprocedural
patient care (radiologist, gynaecologist, or both). The type
of pain management, such as patient-controlled analgesia
(PCA), epidural analgesia, or other—as well as the duration
of hospitalisation—were also inventoried. Speciﬁc proce-
dure-related questions, such as preferred vascular access
(unifemoral, bifemoral, or other), use of microcatheters,
type of embolic agents (gelatin sponge, spherical or non-
spherical embolic material) used, and the advocated em-
bolisation end point (complete stasis, sluggish ﬂow, or
pruned tree appearance), were asked. The use of magnetic
resonance imaging (MRI) for preprocedural and postpro-
cedural evaluation was also discussed. The last items were
aimed at the future expectations of the respondents con-
cerning Magnetic Resonance-guided Focused Ultrasound
(MRgFUS) as a new treatment alternative for uterine ﬁb-
roids,andweaskedifthetreatmentfacilityhadaWebsiteto
allow screening of the Web sites for dedicated information
on UFE treatment. Participants were asked to complete the
online questionnaire before the end of July 2009. To avoid
bias, we decided to include only one survey per treatment
centre. In case more than one questionnaire was returned
from the same facility, we decided to include the ﬁrst
submitted survey in the study and exclude the duplicates.
Results
A total of 282 respondents returned the completed ques-
tionnaire (Table 1). Fifteen questionnaires were excluded
because they were duplicates from treatment centres that
had already returned a questionnaire. The response rate was
therefore 267 of 1,250 candidate treatment centres (21.4%).
Ninety-four respondents (33%) did not perform UFE and
were consequently excluded from the study. Six question-
naires were excluded because essential demographic data
were missing. Further contact efforts to obtain these
missing data did not result in sufﬁcient completion of the
information, thus making rejection of these questionnaires
inevitable. The remaining 167 respondents, all from dif-
ferent UFE centres, were included in the study. The geo-
graphic distribution of the respondents covered 24
countries in Europe, including Turkey. Figure 1 shows the
number of included treatment facilities per country.
Twenty-six percent (n = 43) of the respondents were
from the United Kingdom; 16% (n = 27) were from
Germany; 11% (n = 18) were from France; and the
remainder (53%, n = 79) were from other European
countries. Fifty-two percent (n = 86) of the respondents
worked in an academic centre, and the remaining 48%
(n = 81) worked in a general hospital setting or private
practice. The majority of the respondents (65%, n = 108)
worked in a group with C1 interventional radiologist per-
forming UFE. Only 1% (n = 2) of the respondents
had[15 years of experience with UFE; 25% (n = 42) had
10–15 years of experience; the majority (48%, n = 80) had
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duced UFE during the last 5 years.
Table 2 lists the number of UFE procedures, per year
and per country, classiﬁed into ﬁve categories: B0, 10 to
50, 50 to 100, 100 to 200, and C200 UFE treatments
annually. Most centres (53%, n = 88) performed between
10 and 50 treatments on an annual basis. Extreme numbers
of UFE treatments were provided by two treatment facili-
ties (one in France and one in Romania): They both per-
formed approximately 500 procedures/year.
In Table 3, data on preprocedural, periprocedural, and
postprocedural care management are listed. In the majority
of cases (76%), patients were referred by a gynaecologist
for UFE, and only in a small minority (4%) were referred
by a general practitioner. In the remaining cases (20%),
patients referred themselves directly to the interventional
radiologist. Preprocedural care was generally performed by
a combination of a gynaecologist and radiologist (42%,
n = 70). Preprocedural MRI was considered a standard
procedure by 56% (n = 90) of the responding radiologists.
Pain management was preferably performed (76%,
n = 122) using PCA. Some facilities (15%, n = 24) used
epidural analgesia, and 9% (n = 14) employed other pain-
management protocols, such as intravenous medication
(n = 8), oral medication (n = 1), a combination of PCA
and epidural analgesia (n = 2), general anaesthesia
Table 1 Number of treatment
centres per European country
and response rate
Countries No. of treatment
centres
No. of
respondents
No. of exclusions No. of included
centres (%)
No UFE Duplicates
Austria 54 14 5 0 9 (16.7)
Belgium 27 8 2 1 5 (18.5)
Bulgaria 7 2 1 0 1 (14.3)
Croatia 6 0 0 0 0 (0)
Cyprus 1 0 0 0 0 (0)
Czech Republic 35 2 2 0 0 (0)
Denmark 9 5 3 0 2 (22.2)
Finland 15 3 1 0 2 (13.3)
France 85 20 0 2 18 (21.2)
Germany 289 37 9 1 27 (9.3)
Greece 67 18 15 0 3 (4.5)
Hungary 19 2 0 0 2 (10.5)
Iceland 1 0 0 0 0 (0)
Ireland 14 9 2 1 6 (42.9)
Italy 50 12 6 0 6 (12.0)
Latvia 1 0 0 0 0 (0)
Luxembourg 6 1 1 0 0 (0)
Malta 1 0 0 0 0 (0)
Norway 23 9 3 0 6 (26.1)
Poland 27 3 0 2 1 (3.7)
Portugal 11 2 1 0 1 (9.1)
Romania 6 5 0 4 1 (16.7)
Russia 14 1 0 0 1 (7.1)
Serbia 7 1 1 0 0 (0)
Slovakia 4 1 0 0 1 (25.0)
Slovenia 6 1 0 0 1 (16.7)
Spain 52 12 1 1 10 (19.2)
Sweden 13 4 1 0 3 (23.1)
Switzerland 42 11 6 1 4 (9.5)
The Netherlands 109 30 16 1 13 (11.9)
Turkey 61 6 5 0 1 (1.6)
Ukraine 1 0 0 0 0 (0)
United Kingdom 189 57 13 1 43 (22.8)
Missing demographic data 6
Total 1,250 282 94 15 167 (13.4)
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123(n = 1), superior hypogastric plexus nerve block (n = 1),
and neuroleptic medication (n = 1). Half of the respon-
dents (50%, n = 81) admitted their patients for one
overnight stay after UFE treatment. Only 1% (n = 1)
performed UFE on an outpatient basis, and 3% (n = 5)
admitted their patients for a total of four overnight stays.
Postprocedural care was most frequently (55%, n = 91)
provided by a combination of a gynaecologist and radiol-
ogist. The majority of respondents (72%, n = 120) fol-
lowed-up their patients up for 3 or 6 months, and 8%
(n = 14) did so for[12 months.
InTable 4,UFEprocedure-relateddetailsarelisted.Alarge
majority (81%, n = 134) of the respondents preferred unife-
moral arterial access, whereas 17% (n = 28) chose bifemoral
arterial puncture, and only 2% (n = 3) preferred brachial
arterial access. Spherical embolic material was the favoured
embolic agent in 77% (n = 127) of the responding radiolo-
gists. The frequency of using microcatheters during UFE
procedures varied among the respondents. Only 3% (n = 5)
indicated that they never use them; 36% (n = 60) use them
only when considered necessary; and 34% (n = 56) always
employ microcatheters during UFE. Fourteen percent
(n = 24) used the so-called ‘‘pruned tree’’ appearance on
ﬂuoroscopicimagingastheUFEendpoint.Theuserfrequency
of the end points ‘‘complete stasis’’ and ‘‘sluggish ﬂow’’ was
quite similar (41%, n = 68 vs. 45%, n = 74).
Ninety percent (n = 151) of the treatment facilities had
a Web site. We screened these Web pages for patient
information on UFE. Nineteen percent (n = 31) contained
dedicated passive or interactive treatment information for
patients as well as physicians. Table 5 lists the annual
number of treatments per centre in ﬁve categories for
centres with and without a dedicated UFE Web site. This
table illustrates that centres providing UFE information on
a Web site have higher treatment numbers than facilities
not operating an active Web site.
Future expectations for MR-HIFU as a thermoablative
therapy for ﬁbroids were indicated as ‘‘very promising’’ by
ﬁve % (n = 9) of the respondents; 30% (n = 50) thought it
was ‘‘promising,’’ and 28% (n = 47) did not see an
important role for this treatment in the future. The
remaining 36% (n = 60) had no opinion about this topic.
Discussion
Since the publications of Ravina et al. in the early 1990s on
premyomectomy transcatheter embolisation to minimize
bloodlossduringsurgery,thesurprisingeffectsondecreased
ﬁbroidsizeandsymptomsbecameevidentandledtotheﬁrst
reports on UFE as a single treatment for symptomatic ﬁb-
roids [2, 4]. After a worldwide introduction as a possible
alternative to hysterectomy and many additional studies on
this treatment, UFE now seems to ﬁt into the treatment
options available to women suffering from uterine ﬁbroids.
The Cochrane review from 2006 cited that UFE resulted
in the same patient satisfaction rate as surgery (myomec-
tomy or hysterectomy) [5]. The length of hospital stay was
decreased after UFE, and the return to daily activities was
faster. Because UFE seemed to result in a higher minor
complication rate and more unscheduled visits and read-
mission rates, the statement was made that additional focus
Fig. 1 Number of included
treatment facilities per
European country
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123on long-term follow-up was necessary to determine the real
impact of UFE [6].
As a result, retrospective cohort studies examined and
compared the results of UFE and hysterectomy, which lead
to satisfying conclusions concerning safety, expectations,
and cost-effectiveness over a longer follow-up period
[7, 8]. Furthermore, randomized studies comparing UFE
and surgery (hysterectomy or myomectomy) have been
completed in the meantime, resulting in publications in
major scientiﬁc journals [9–12]. However, in gynaecolog-
ical papers, the experimental character of UFE was only
recently abandoned. Short, medium, and long-term follow-
up data are currently available, leading to a more positive
attitude from our gynaecological colleagues [3, 13, 14].
Guidelines from different medical specialities currently
consent that UFE is a valuable alternative to surgical
management of symptomatic ﬁbroids in carefully selected
and informed patients [6, 15]. Bratby et al. quoted that
level 1 evidence has established the role of UFE as a proper
alternative treatment [16]. Last but not least, Bradley et al.
stated that UFE is effective, safe, and durable and should
be considered a true alternative to hysterectomy [3].
Apparently, the Cochrane review from 2006 is consider-
ably outdated and must be revised as soon as possible.
This current European survey showed interesting ﬁnd-
ings on clinical UFE practice in a variety of treatment
centres in different European countries. It was nevertheless
interesting to discover the marked variation in current UFE
practice across European centres in terms of distribution,
approach, treatment care, and numbers. The top ﬁve of
countries with the highest number of UFE centres were
(starting with the highest) the United Kingdom, Germany,
France, The Netherlands, and Spain. UFE facilities were not
exclusively restricted to academic centres (52%), as prob-
ably could be expected, but were also present in general
hospital and/or private settings. Our survey also illustrates
that although in 2009 UFE was widespread throughout
European countries, the majority of centres (53%) per-
formed only between 10 and 50 UFE procedures/year. Only
5% performed [100 cases annually. Most respondents
(65%) were active in a group of interventionalists per-
forming UFE, providing potential 24-h/7-day coverage of
patient care. The overall impression that UFE is not new in
Europewasexpressedbythefactthatthemajorityofcentres
(74%) had[5 years of experience with UFE.
Participation with gynaecologists was performed by the
majority of interventionalists in both preprocedural (42%)
and postprocedural (55%) patient care. Preprocedural and
Table 2 Annual number of
UFE procedures (classiﬁed into
ﬁve categories) performed in
treatment facilities per country
n Number of treatment facilities
Countries (n) B10 10 to\50 50 to\100 100 to\200 C200
Austria (n = 9) 2 7 0 0 0
Belgium (n = 5) 1 4 0 0 0
Bulgaria (n = 1) 1 0 0 0 0
Denmark (n = 2) 0 2 0 0 0
Finland (n = 2) 1 1 0 0 0
France (n = 18) 5 10 1 1 1
Germany (n = 27) 11 14 1 1 0
Greece (n = 3) 2 1 0 0 0
Hungary (n = 2) 0 0 2 0 0
Ireland (n = 6) 1 3 1 1 0
Italy (n = 6) 6 0 0 0 0
Norway (n = 6) 3 3 0 0 0
Poland (n = 1) 0 0 1 0 0
Portugal (n = 1) 0 1 0 0 0
Romania (n = 1) 0 0 0 0 1
Russia (n = 1) 1 0 0 0 0
Slovakia (n = 1) 0 1 0 0 0
Slovenia (n = 1) 1 0 0 0 0
Spain (n = 10) 4 6 0 0 0
Sweden (n = 3) 2 1 0 0 0
Switzerland (n = 4) 3 1 0 0 0
The Netherlands (n = 13) 7 5 0 1 0
Turkey (n = 1) 1 0 0 0 0
United Kingdom (n = 43) 8 28 5 1 1
Total number (%) of treatment
facilities (n = 167)
60 (36) 88 (53) 11 (6) 5 (3) 3 (2)
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123postprocedural care solely by IR was noted in only 17 and
21% of centres, respectively. Gynaecologists were the
main referrers for UFE treatment. The preferred pain-
management in the majority of centres (76%) was PCA, as
expected, and most centres (50%) admitted the patients for
one overnight stay after the procedure.
In terms of facility-related efﬁcacy estimation, it was
disappointing to note that only 24% of centres followed-
up their patients for C12 months, 31% for only 6 months,
and the majority (41%) for only 3 months. Although
he use of preprocedural and postprocedural MRI is
advocated widely to properly map and follow-up a UFE
candidate, only 56% of centres employed a pre-UFE
MRI-planning protocol. Postprocedural MRI follow-up
was even more disappointing, probably related to the
poor follow-up intervals as stated previously. Contrast-
enhanced MRI is by all means the only reliable imaging
modality to obviate sufﬁcient devascularisation, e.g., a
technically successful embolisation.
The fact that most centres (81%) used a unifemoral
arterial access for UFE minimizes the concern about
potential adverse events occurring at the puncture sites, and
using the Waltman loop manoeuvre might also be of great
help in cases of steep aortic bifurcation issues. Although
66% of interventional radiologists do not use microcathet-
ers, or use them only if necessary, coaxial use of micro-
catheters might be important to avoid vascular spasms,
resulting in inadequate devascularisation of ﬁbroids, thus
leading to inferior clinical results. The chosen embolisation
end point may depend on the type of embolisation material
Table 3 Preprocedural, periprocedural, and postprocedural care-
related information
% N
Referral for UFE (n = 165)
Self-referral 20 –
Gynaecologist 76 –
General practitioner 4 –
Preprocedural care (n = 166)
Radiologist 17 28
Gynaecologist 41 68
Combination 42 70
Pain management (n = 160)
Patient-controlled analgesia (PCA) 76 122
Epidural analgesia 15 24
Other 9 14
Length of hospital stay (n = 163)
Outpatient treatment 1 1
1 night 50 81
2 nights 33 54
3 nights 13 22
4 nights 3 5
Postprocedural care (n = 166)
Radiologist 21 35
Gynaecologist 24 40
Combination 55 91
Postprocedural follow-up schedule (n = 166)
No follow-up 4 6
Follow-up for 3 months 41 69
Follow-up for 6 months 31 51
Follow-up for 12 months 16 26
Follow-up for[12 months 8 14
Planned MRI scan (n = 161)
Preprocedure 56 90
3 months postprocedure 18 29
6 months postprocedure 21 34
9 months postprocedure 0 0
12 months postprocedure 4 7
[12 months postprocedure 1 1
n Number of respondents who answered the speciﬁc question
Table 4 UFE procedure-related information
% N
Preferred arterial access (n = 165)
Unifemoral 81 134
Bifemoral 17 28
Brachial 2 3
Embolic agent (n = 166)
Gelatin sponge 1 2
Spherical embolic material 77 127
Nonspherical embolic material 22 37
Use of microcatheters (n = 166)
Never 3 5
Seldom 36 60
Regularly 27 45
Always 34 56
End point used (n = 166)
Complete stasis 41 68
Sluggish ﬂow 45 74
Pruned tree 14 24
n Number of respondents who answered the speciﬁc question
Table 5 Number of UFE treatments per category for centres with
and without a dedicated UFE Web site
No. of UFE procedures/year % UFE Web site presence (n)
No (136) Yes (31)
B10 41 (56) 13 (4)
10 to\50 51 (69) 61 (19)
50 to\100 6 (8) 10 (3)
100 to\200 1 (2) 10 (3)
C200 1 (1) 7 (2)
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123used. In the minority of centres, the pruned-tree appearance
on ﬂuoroscopic images is still used as the end point indi-
cator. Sluggish ﬂow in the uterine artery, e.g., the Shlansky-
Goldberg method (stasis during ﬁve heartbeats) [17], was
employed in equal frequency as total stasis of contrast
medium in the uterine artery. Concerning embolisation
material, no solid conclusive data are available to date on
superior clinical outcome after UFE with a certain type
embolic agent, although studies are pointing in the direction
of calibrated microspheres [18–21]. It was therefore inter-
esting to notice that a large majority of centres (77%)
favoured the use of these microspheres. Gelatin sponge was
still employed in 1% of the centres. Although the role of the
industry in promoting spherical embolic agents cannot be
underestimated, the advantages of calibrated microspheres
during UFE procedures, especially when using microcath-
eters,areevident.Lesscloggingofmicrocathetersandbetter
prediction of the level of devascularisation might result in a
smooth, swift, and successful UFE procedure.
Some treatment centres have dedicated ﬁbroid clinics
for preprocedural consultation and postembolisation clini-
cal and radiologic follow-up. These centres of excellence
often employ well-designed and properly executed public
relations focused on potential patients and referring phy-
sicians. Kroencke stated the importance of using the media
to enhance patient awareness of treatment options [22]. We
should not underestimate the inventiveness of modern
patients in their search for alternative treatment options
independent from their treating physician. Not only the
Internet, but also magazines, radio, and television, can be
used by treatment centres to reach potential patients. The
creation of an interactive Web site is a unique opportunity
to do so. This study indicated that treatment centres oper-
ating a Web site containing dedicated UFE information
performed more procedures than centres that do not use
Web site possibilities, thus emphasizing the efﬁcacy of
such strategies. However, the presence of such a Web site
might not be the only explanation for this ﬁnding.
Another important point in building a UFE practice is
that interventional radiologists must become accustomed to
treating patients in a clinical environment. UFE treatments
must be performed by a multidisciplinary team, including
gynaecologists and anaesthesiologists. It is extremely
important, as quoted by Keeling et al., that interventional
radiologists see the patient in the ﬁrst place instead of a
uterine ﬁbroid that must be embolised [23]. Although
quality of care is becoming increasingly important, it is no
longer acceptable to meet the patient in the angiographic
suite for the ﬁrst time, perform the embolisation procedure,
and never see her again.
Concerning new therapeutic developments, it was amaz-
ing to notice that Magnetic Resonance-guided Focused
Ultrasound was categorized as a ‘‘very promising’’
respectively ‘‘promising’’ new treatment option by only 5%
respectively 30% of the centres. Thirty-six percent did not
see any role for MRgFUS in the future. However, recent
papers show that MRgFUS can be a treatment option with
satisfyingresultsforaselectionofpatients [24–26].Thelow
levels of conﬁdence we found might be partially biased by
uneasy feelings toward a possible competitive treatment for
UFE. Another reason could be that MRgFUS devices are
expensive to acquire and therefore many of the respondents’
facilities will never have the opportunity to obtain one.
Moreover, current focused ultrasound technology can treat
only relatively small volumes of ﬁbroid tissue at a time, and
respondents might see this is an essential factor limiting the
number of patients that can be treated with this technique.
A limitation of this study was the low response rate
(21.4%). All CIRSE members received an invitation to
participate in this online questionnaire; however, only a
relatively small percentage responded. Therefore, we do
not have the illusion of possessing a solid and complete
data set on this subject because not all centres performing
UFE completed the questionnaire. A low response rate is
always a problem when conducting a survey, and it tends to
be even lower when using an electronic survey instead of a
survey sent by postal mail [27, 28]. Therefore, the results
published here are not an absolute view on UFE practice in
Europe. It is possible that the nonresponding interventional
centres do not perform UFE except, for instance, only
nonvascular interventions. Another possibility is that some
of the centres performing UFE are not members of CIRSE
and therefore did not receive a survey invitation. Moreover,
a key issue in survey research is nonresponse bias, which
occurs when respondents differ in meaningful ways from
nonrespondents. It is possible that the responders are more
actively involved in this subject than nonresponders and
are therefore more willing to participate in this survey.
We conclude with the statement that UFE as an alter-
native treatment for hysterectomy or myomectomy is
widespread in Europe. However, the impact on the man-
agement of the patient with symptomatic ﬁbroid seemed,
according to the overall numbers of UFE procedures, dis-
appointing. A more active attitude toward clinical IR,
together with effective public relations, might establish a
more solid fundament for UFE treatment in the future.
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Demographic information
Name institution: 
Name respondent: 
In which country are you working: 
In which city are you working: 
Do you perform Uterine Fibroid Embolisation (UFE)?  Yes     No 
Interventional group
How many interventionalists are in your group?  I am alone 
1 physician 
 2  physicians 
 3  physicians 
 4  physicians 
How many interventionalists in your group perform UFE:
When did your group start performing UFE (year): 
How many procedures does your group perform annually: 
Patient care
Could you indicate the percentages of referrals  
(adding up to 100%):
Self (patient):            % 
Gynaecology: % 
General Practitioner:    % 
Who provides the pre-treatment care?  Self (radiologist) 
Gynaecologist 
 Combination 
Who provides after care?  Self (radiologist) 
Gynaecologist 
 Combination 
Procedure
Pain management:  PCA (patient controlled 
analgesia) 
Epidural 
 Other: 
Which vascular access site do you prefer?  Unifemoral 
 Bifemoral 
 Other: 
Do you use microcatheters?   Never 
 Seldom 
 Regularly 
 Always 
Which embolic agent do you use?   Gelfoam 
 Spherical 
 Non-spherical 
What do you use as endpoint during your procedures?   Complete  stasis 
 Sluggish  flow 
 Pruned  tree 
How long is the hospital stay?   Outpatient  basis 
  1 night stay 
  2 nights stay 
  3 nights stay 
  4 nights stay 
  5 nights stay 
What is your follow-up schedule?   No  follow-up 
 3  months 
 6  months 
 12  months 
 >  12  months 
When do you perform an MRI scan?   Pre-procedural 
  3 months post-procedural 
  6 months post-procedural 
  9 months post-procedural 
  12 months post-procedural 
  > 12 months post-procedural 
General
Does your institution have a website?   No 
 Yes:   
How many UFE procedures do you expect for 2009: 
What do you expect of MRI-guided focused ultrasound?   Very  promising 
 Promising 
 Nothing 
 Do  not  know 
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